Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis , Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Bahia Metals Files NI 43-101 Technical Report for Initial 313 Million Tonne Mangueiros Main Inferred Mineral Resource Estimate
GoldInxs Advances Fishpot Toward Maiden Drill Program with New 3D IP Survey, Magnetic and Virtual DRILL Results
